Close this search box.

Santa Ana: Leveraging human multi-omic data for precision immunology

ARTICLE | Emerging Company Profile

Versant-founded immunology play launches with $168M to create biologics targeted to specific cell types

By Danielle Golovin, Senior Biopharma Analyst

June 13, 2024 11:00 PM UTC

Santa Ana is leveraging learnings from precision oncology and combining them with advances in protein engineering capabilities to create biologics for precision immunology.

Santa Ana Bio Inc. uses genomic, transcriptomic and proteomic approaches to characterize patient subpopulations and identify targets expressed only on disease-causing cell types, leaving healthy cells unaffected…